Israel - English - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1500 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locallyadvanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreaticcancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage.breast cancer:gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locallyrecurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.prior chemotherapy should have included an anthracycline unless clinically contraindicated.ovarian cancer:gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelialovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - gemcitabine hydrochloride, quantity: 228 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; sodium acetate trihydrate - treatment of patients with locally advanced or metastatic non-small cell lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. treatment of patients with fu refractory pancreatic cancer. treatment of patients with bladder cancer, alone or in combination with cisplatin. treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed >six months following platinum based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - gemcitabine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - gemcitabine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - gemcitabine hydrochloride -

Israel - English - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 200 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1000 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gemcitabine hydrochloride, quantity: 1139 mg (equivalent: gemcitabine, qty 1000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections; sodium acetate trihydrate - gemcitabine sandoz is indicated for treatment of patients with:. - locally advanced or metastatic non-small cell lung cancer (nsclc). - locally advanced or metastatic adenocarcinoma of the pancreas . - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.. - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Israel - English - Ministry of Health

novartis israel ltd - gemcitabine as hydrochloride - concentrate for solution for infusion - gemcitabine as hydrochloride 40 mg / 1 ml - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - English - Ministry of Health

abic marketing ltd, israel - gemcitabine as hydrochloride - concentrate for solution for infusion - gemcitabine as hydrochloride 40 mg/ml - gemcitabine - gemcitabine - gemcitabine teva® concentrate is indicated for the palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer.gemcitabine teva® concentrate is indicated for the treatment of patients with bladder cancer at the invasive stage.breast cancer:gemcitabine teva® concentrate in combination with paclitaxel,is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant /neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.ovarian cancer:gemcitabine teva® concentrate in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed at least 6 months after platinum-based therapy.